Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Jaume Capdevila Castillón

9PUBLICATIONS

99CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiological adaptationCancer diagnosis

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Apr 04, 2026

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo

|Sep 12, 2025

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo

|Apr 08, 2025

Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.

Carlota Arenillas, Lucía Celada, José Ruiz-Cantador

|Aug 08, 2024

Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso

|Dec 05, 2023

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.

Paul B Romesser, Jaume Capdevila, Rocio Garcia-Carbonero

|May 23, 2023

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

J Capdevila, J Hernando, A Teule

Pageof 2

Frequent Collaborators

3 joint publications

Alex Teule

3 joint publications

Alejandro Garcia-Alvarez

3 joint publications

Paolo Nuciforo

3 joint publications

Rocio Garcia-Carbonero

2 joint publications

Alberto Carmona-Bayonas

1 joint publications

G Crespo

1 joint publications

S Landolfi

1 joint publications

Paul B Romesser

1 joint publications

Tony Philip

1 joint publications

Carlos Fernandez Martos

Frequent Collaborators

3 joint publications

Alex Teule

3 joint publications

Alejandro Garcia-Alvarez

3 joint publications

Paolo Nuciforo

3 joint publications

Rocio Garcia-Carbonero

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on : Aug 02, 2018

See more related videos

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on : Aug 02, 2018

See more related videos